S1222 Trial (Everolimus, Anastrozole and Fulvestrant) in Post-Menopausal Stage IV Breast Cancer

Stopped early · Phase 3 · Has a placebo group

Conditions studied: Breast Cancer

In brief

This randomized Phase III trial studies how well the combination of fulvestrant and everolimus together or the combination of anastrozole, fulvestrant and everolimus together, improve progression-free survival (PFS) versus fulvestrant alone.

Key facts

Study ID
NCT02137837
Run by
SWOG Cancer Research Network
People needed
37
Starts
2014-05-01
Expected to finish
2019-12-31
Last updated by the study team
2021-01-28

Who can join

Age: 18 and older. Sex: female. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.